Bioequivalence test is unlikely to be effective

Published: 2002-08-05 06:58:00

Updated: 2002-08-05 06:58:00

In the regular business report by the Korea Food and Administration (KFDA), the parliamentary members belonging to the Committee of Health and Welfare pointed out that the bioequivalence test has proven to be ineffective as a government drug related policy and this has little contributed to activ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK